Physician profile
Mile Brujic
NPI 1659474120
$1,310,400.43
in general payments reported to CMS, 2019-2025
38 companies · $289K in 2025
The $289K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144K · 2020: $105K · 2021: $171K · 2022: $251K · 2023: $150K · 2024: $200K · 2025: $289K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $253K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $155K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $155K · Travel and Lodging: $59K · Food and Beverage: $18K · Honoraria: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $252,823.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $154,828.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $154,576.50 |
| Travel and Lodging | $59,172.71 |
| Food and Beverage | $17,596.63 |
| Honoraria | $589.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $378,963.82 | 2022-2025 | Miebo, Xiidra, Biotrue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140,385.24 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $110,137.22 | 2024-2025 | Xdemvy |
| Abbvie INC. | $107,018.53 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Sun Pharmaceutical Industries INC. | $101,941.67 | 2019-2025 | Cequa |
| Nordic Pharma, INC. | $62,840.77 | 2024-2025 | Lacrifill, Lacrifill |
| Allergan, INC. | $61,454.78 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $49,293.20 | 2019-2022 | |
| Alcon Vision LLC | $38,304.88 | 2019-2025 | Tryptyr, Precision 1, Eysuvis |
| Abb Con-Cise Optical Group LLC | $38,282.88 | 2023-2025 | Contact Lens |
| Novartis Pharmaceuticals Corporation | $35,839.86 | 2019-2023 | Xiidra |
| Shire North American Group INC | $31,733.67 | 2019 | |
| Sight Sciences, INC. | $30,741.64 | 2019-2025 | Tearcare System |
| Oyster Point Pharma, INC. | $29,528.29 | 2022-2025 | Tyrvaya, Ryzumvi, Phentolamine Mesylate |
| Eyevance Pharmaceuticals LLC | $24,924.19 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $14,196.19 | 2022-2024 | Iyuzeh |
| Apellis Pharmaceuticals, INC. | $13,612.47 | 2023-2025 | Syfovre, Syfovre |
| Coopervision INC. | $6,927.40 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Alcon Research LLC | $6,900.00 | 2019-2025 | Tryptyr |
| Glaukos Corporation | $6,584.43 | 2023-2025 | Radius, Radius Xr, Kxl System (Not Refurbished) |
| Horizon Therapeutics Plc | $4,408.62 | 2020-2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $3,986.19 | 2019-2020 | |
| Optovue, INC. | $3,683.62 | 2019-2021 | |
| Dompe US, INC. | $3,032.82 | 2019-2025 | Oxervate |
| Maculogix, INC. | $1,527.46 | 2020-2021 | |
| Immunogen, INC. | $1,299.55 | 2023 | Elahere |
| Eyepoint US, INC. | $854.00 | 2019 | |
| Quidel Corporation | $720.90 | 2019-2022 | |
| Akorn, INC. | $500.00 | 2019 | |
| Biotissue Holdings INC. | $181.33 | 2025 | |
| Harrow Eye, LLC | $133.23 | 2025 | Vevye |
| Ortho-Clinical Diagnostics, INC. | $107.27 | 2024 | |
| Mallinckrodt Hospital Products INC. | $105.68 | 2024-2025 | Acthar |
| Synergeyes, INC. | $88.00 | 2020 | |
| Visionix USA, INC | $83.21 | 2022 | |
| Optos, INC. | $39.61 | 2021 | |
| Vantage Technology LLC | $21.20 | 2023 | |
| Visioneering Technologies, INC. | $16.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mile Brujic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.